Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shim, V.
Right arrow Articles by Esserman, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shim, V.
Right arrow Articles by Esserman, L. J.
[Cancer Research 63, 2347-2350, May 15, 2003]
© 2003 American Association for Cancer Research

Advances in Brief

Cyclooxygenase-2 Expression Is Related to Nuclear Grade in Ductal Carcinoma in Situ and Is Increased in Its Normal Adjacent Epithelium1

Veronica Shim2, Mona L. Gauthier2, Daniel Sudilovsky, Kristin Mantei, Karen L. Chew, Dan H. Moore, Imok Cha, Thea D. Tlsty and Laura J. Esserman3

University of California at San Francisco Comprehensive Cancer Center [V. S., K. L. C., D. H. M., L. J. E.], Department of Pathology [M. L. G., K. M., I. C., T. D. T.], University of California, San Francisco, California 94115-1710, and California Pacific Medical Center, San Francisco, California [D. S.]

Cyclooxygenase-2 (COX-2) is emerging as an important cancer biomarker and is now an experimental target for solid tumor treatment.However, no study has exclusively focused on COX-2 expression in early lesions such as ductal carcinoma in situ (DCIS). We examined COX-2 expression by immunohistochemistry in 46 cases of women undergoing surgical resection for DCIS. We found that COX-2 expression was detected in 85% of all DCIS specimens, with increased COX-2 staining correlating with higher nuclear grade. Strikingly, COX-2 staining intensity in the normal adjacent epithelium was stronger than in the DCIS lesion itself. Our observations demonstrate that COX-2 is up-regulated in the normal adjacent epithelium and supports the hypothesis that the surrounding epithelial tissue is part of the disease process in DCIS.




This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
D. W. Visscher, V. S. Pankratz, M. Santisteban, C. Reynolds, A. Ristimaki, R. A. Vierkant, W. L. Lingle, M. H. Frost, and L. C. Hartmann
Association Between Cyclooxygenase-2 Expression in Atypical Hyperplasia and Risk of Breast Cancer
J Natl Cancer Inst, March 19, 2008; 100(6): 421 - 427.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Zhao, M. Goswami, N. Pokhriyal, H. Ma, H. Du, J. Yao, T. A. Victor, K. Polyak, C. D. Sturgis, H. Band, et al.
Cyclooxygenase-2 Expression during Immortalization and Breast Cancer Progression
Cancer Res., January 15, 2008; 68(2): 467 - 475.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Subbaramaiah, L. R. Howe, E. R. Port, E. Brogi, J. Fishman, C. H. Liu, T. Hla, C. Hudis, and A. J. Dannenberg
HER-2/neu Status Is a Determinant of Mammary Aromatase Activity In vivo: Evidence for a Cyclooxygenase-2-Dependent Mechanism.
Cancer Res., May 15, 2006; 66(10): 5504 - 5511.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. R. Howe, S.-H. Chang, K. C. Tolle, R. Dillon, L. J.T. Young, R. D. Cardiff, R. A. Newman, P. Yang, H. T. Thaler, W. J. Muller, et al.
HER2/neu-Induced Mammary Tumorigenesis and Angiogenesis Are Reduced in Cyclooxygenase-2 Knockout Mice
Cancer Res., November 1, 2005; 65(21): 10113 - 10119.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
K-B Tan and T C Putti
Cyclooxygenase 2 expression in nasopharyngeal carcinoma: immunohistochemical findings and potential implications
J. Clin. Pathol., May 1, 2005; 58(5): 535 - 538.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. L. Gauthier, C. R. Pickering, C. J. Miller, C. A. Fordyce, K. L. Chew, H. K. Berman, and T. D. Tlsty
p38 Regulates Cyclooxygenase-2 in Human Mammary Epithelial Cells and Is Activated in Premalignant Tissue
Cancer Res., March 1, 2005; 65(5): 1792 - 1799.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. W. Yim, H.-S. Jong, T. Y. Kim, H. H. Choi, S. G. Kim, S. H. Song, J. Kim, S.-G. Ko, J. W. Lee, T.-Y. Kim, et al.
Cyclooxygenase-2 Inhibits Novel Ginseng Metabolite-Mediated Apoptosis
Cancer Res., March 1, 2005; 65(5): 1952 - 1960.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Miyoshi, S. J. Kim, K. Akazawa, S. Kamigaki, S. Ueda, T. Yanagisawa, T. Inoue, T. Taguchi, Y. Tamaki, and S. Noguchi
Down-Regulation of Intratumoral Aromatase Messenger RNA Levels by Docetaxel in Human Breast Cancers
Clin. Cancer Res., December 15, 2004; 10(24): 8163 - 8169.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
R. N. DuBois
Aspirin and Breast Cancer Prevention: The Estrogen Connection
JAMA, May 26, 2004; 291(20): 2488 - 2489.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.